Harmony Biosciences Holdings, Inc. (NasdaqGM: HRMY)
Health Care · Pharmaceuticals · US
$38.15
+0.21% today · +2.3% 1Y
Harmony Biosciences Holdings, Inc. (NasdaqGM: HRMY) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.22B and employs 293 people.
Over the last twelve months the share price has gained 2.3%, trading between 25.52 and 40.87.
Tweenvest scores Harmony Biosciences Holdings, Inc. across four factors: quality 76/100, value 76/100, growth 100/100. Its strongest factor is growth.
HRMY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.22B
- Revenue (TTM)
- $959.90M
- P/E
- 12.34
- EPS
- 3.09
- Dividend yield
- —
- Beta (5Y)
- 0.91
- 52-week high
- $40.87
- 52-week low
- $25.52
- Avg volume (3M)
- —
- Shares outstanding
- 58.24M
- Employees
- 293
- Next earnings
- —
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
- Founded
- 2017
- Listed since
- Aug 19, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.